EMA Updates Flu Vaccination Recommendations
The agency issued its recommendation for the influenza virus strains European vaccine manufacturers should include for 2017.
The European Medicines Agency announced on April 12, 2017 that it had issued an update on the recommendations for influenza flu strains that vaccine manufacturers should include in their vaccines for the autumn 2017 season. The updates were developed by the Ad hoc Influenza Working Group of the Biologics Working Party (BWP) and based on information provided by the World Health Organization.
A decision on a suitable A/Michigan/45/2015 (H1N1)pdm09-like virus strain for live, attenuated vaccines and the specific virus strains recommended are included in the recommendations. Marketing authorization holders should submit applications to change the composition of centrally authorized seasonal flu vaccines by June 12, 2017.
Source: EMA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
